Fluoxetine – realizing the drug’s potential Case report
Article Sidebar
Main Article Content
Abstract
Fluoxetine – one of the first so-called “new generation” antidepressants, was approved for marketing in the US by the Food and Drug Administration in December 1987, and appeared on the market in January 1988. It has been available in Poland since the early 1990s. Its appearance was associated with the dissemination, both among doctors and patients, of knowledge about depression – symptoms and treatment methods. The consequence was a change in the negative perception of depression and antidepressants. Many people have become convinced that they can better cope with the disease thanks to these drugs. This paper presents the most important information about the drug and the possibilities for its use in daily clinical practice.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Charakterystyka Produktu Leczniczego Bioxetin z 18.02.2014 r.
3. Sohel AJ, Suutter MC, Patel P et al. Fluoxetine. In: StatPearls Publishing; 2024 Jan.
4. Schneier FR, Liebowitz MR, Davies SO et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990; 10(2): 119-21. http://doi.org/10.1097/00004714-199004000-00007.
5. Riggin L, Frankel Z, Moretti M et al. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2013; 35(4): 362-9.
6. Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development; Bethesda (MD): 2023. Fluoxetine.
7. Narouze S, Benzon HT, Provenzano D et al. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018; 43(3): 225-62.
8. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016; 6(4): 191-6.
9. Amsterdam J, Garcia-España F, Fawcett J et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. J Affect Disord. 1999; 55(1): 11-7. http://doi.org/10.1016/s0165-0327(98)00203-1.
10.Azizi M, Khani S, Kamali M et al. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. Iran J Med Sci. 2022; 47(3): 173-93. http://doi.org/10.30476/ijms.2020.87687.1817.